Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;114(3):236-250.
doi: 10.1016/j.jnma.2022.01.004. Epub 2022 Mar 21.

Cancer healthcare disparities among African Americans in the United States

Affiliations
Review

Cancer healthcare disparities among African Americans in the United States

Edith Mitchell et al. J Natl Med Assoc. 2022 Jun.

Abstract

A need exists to examine racial disparities in the healthcare arena and the impact on patients with cancer. Despite ongoing efforts to increase equity in primary healthcare access, racial and socioeconomic disparities persist, thus contributing to disproportionate treatment outcomes and survivorship among minority and low-income patients. Such disparities have been revealed in treatment cohorts of patients with multiple forms of cancer, including breast, cervical, ovarian, endometrial, prostate, lung, colorectal, gastrointestinal, and hepatocellular, and have been attributed to a range of co-occurring behavioral, social determinants of health, underlying genetic factors, as well as access to educational opportunities that limit the quality of informed healthcare. These various interrelated factors widen cancer healthcare disparities synergistically throughout underserved communities, and their influence has been amplified by the coronavirus disease 2019 (COVID-19) pandemic. Fundamentally, a lack of basic and clinical research exists that fails to adequately reflect diversity and minority involvement in drug development. Although overcoming the obstacles responsible for chronic treatment disparities is a formidable task, promising means of achieving more uniform quality healthcare are becoming more clearly elucidated. To reduce disease progression, increase overall survival, and improve the health of vulnerable populations, it is necessary to identify and fully disclose environmental, biological, and ancestral factors that impact the risk for cancer; heal historical fractures within communities; and increase participation of racial and ethnic minorities in screening efforts and research studies. This requires developing a system of justice and trust based on specific, solution-oriented grassroots community efforts working in tandem with medical and pharmaceutical leaders. By fully exploring and pinpointing the underlying causes of healthcare disparities, it should be possible to define strategies and interventions most likely to transform cancer care. The ultimate goal is understanding individual, cultural, and biological vulnerabilities, including environmental and epigenetic liabilities, to optimize cancer prevention, diagnosis, and treatment.

Keywords: Cancer healthcare disparities; Underserved populations.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Edith Mitchell reports being a paid consultant for Genentech, Taiho, Bristol Myers Squibb, Exelexis. She has also been employed by Genentech, Bristol Myers Squibb, Taiho. Olatunji Alese reports clinical trial funding paid to institution from Taiho Oncology, Ipsen Pharmaceuticals, GSK, Bristol Myers Squibb, PCI Biotech AS, Calithera Biosciences, Inc., SynCore Biotechnology Co., Ltd., Corcept, Mabspace Biosciences. He also reports being a paid consultant for Exelixis, Conjupro BioTherapeutics, R-Pharm US LLC, Ipsen Pharmaceuticals, Natera, Taiho, Pfizer, QED Therapeutics. Clayton Yates reports receiving research support from Riptide Biosciences. He also reports being a consultant and advisor for Riptide Biosciences. Brian Rivers has nothing to report. William Blackstock has no conflict of interest to report. Lisa Newman reports receiving grant support from Genentech. Melissa Davis reports receiving grant support from Genentech. Goldie Byrd has nothing to report. Adalynn Harris reports having previously been employed by QED Therapeutics.

Similar articles

Cited by

LinkOut - more resources